Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 7,70,500 crores |
| Non-Institutional Investors (NIIs) | 15% | 2,31,150 crores |
| Retail Individual Investors (RIIs) | 35% | 5,39,350 crores |
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| 12 Nov '25 | 14 Nov '25 | 13 Nov '25 |
| Issue Composition: | |
|---|---|
| Face Value | ₹0 per share |
| Total Issue Size | 15,41,000 shares (aggregating up to ₹2,56,000 crores) |
| Fresh Issue | NaN shares (aggregating up to To be announced) |
| Offer for Sale | NaN shares of ₹0 (aggregating up to To be announced) |
| Issue Type | |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | shares |
| Post-Issue Shareholding | 0 shares |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Curis Lifesciences ipo has been designed to ensure broad participation while maintaining optimal price discovery.
| Book Running Lead Manager(s) |
|---|